Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology

Wenlin Hao, Yang Liu, Shirong Liu, Silke Walter, Marcus O. Grimm, Amanda J. Kiliaan, B. Penke, Tobias Hartmann, Claudia E. Rübe, Michael D. Menger, Klaus Fassbender

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Alzheimer's disease is characterized by extracellular deposits of amyloid β peptide in the brain. Increasing evidence suggests that amyloid β peptide injures neurons both directly and indirectly by triggering neurotoxic innate immune responses. Myeloid differentiation factor 88 is the key signalling molecule downstream to most innate immune receptors crucial in inflammatory activation. For this reason, we investigated the effects of myeloid differentiation factor 88-deficient bone marrow cells on Alzheimer's disease-related symptoms and pathology by establishing bone marrow chimeric amyloid β peptide precursor transgenic mice, in which bone marrow cells differentiate into microglia and are recruited to amyloid β peptide deposits. We observed that myeloid differentiation factor 88-deficient bone marrow reconstruction reduced both inflammatory activation and amyloid β peptide burden in the brain. In addition, synaptophysin, a marker of neuronal integrity, was preserved and the expression of neuronal plasticity-related genes, ARC and NMDA-R1, was increased. Thus, myeloid differentiation factor 88-deficient microglia significantly improved the cognitive function of amyloid β peptide precursor protein transgenic mice. Myeloid differentiation factor 88-deficiency enhanced amyloid β peptide phagocytosis by microglia/macrophages and blunted toxic inflammatory activation. Both the expression of amyloid β peptide precursor protein and amyloid β peptide degrading enzymes and also the efflux of amyloid β peptide from brain parenchyma were unaffected by myeloid differentiation factor 88-deficient microglia. By contrast, the activity of β-secretase was increased. β-Secretase is expressed primarily in neurons, with relatively little expression in astrocytes and microglia. Therefore, microglial replenishment with myeloid differentiation factor 88-deficient bone marrow cells might improve cognitive functions in Alzheimer's disease mouse models by enhancing amyloid β peptide phagocytosis and reducing inflammatory activation. These results could offer a new therapeutic option that might delay the progression of Alzheimer's disease.

Original languageEnglish
Pages (from-to)278-292
Number of pages15
JournalBrain
Volume134
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Myeloid Differentiation Factor 88
Bone Marrow Cells
Alzheimer Disease
Pathology
Amyloid
Peptides
Microglia
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Amyloid Plaques
Phagocytosis
Cognition
Transgenic Mice
Brain
Bone Marrow
AIDS-Related Complex
Neurons
Synaptophysin
Neuronal Plasticity
Poisons

Keywords

  • Alzheimer's disease
  • inflammation
  • microglia
  • MyD88
  • phagocytosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Hao, W., Liu, Y., Liu, S., Walter, S., Grimm, M. O., Kiliaan, A. J., ... Fassbender, K. (2011). Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain, 134(1), 278-292. https://doi.org/10.1093/brain/awq325

Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. / Hao, Wenlin; Liu, Yang; Liu, Shirong; Walter, Silke; Grimm, Marcus O.; Kiliaan, Amanda J.; Penke, B.; Hartmann, Tobias; Rübe, Claudia E.; Menger, Michael D.; Fassbender, Klaus.

In: Brain, Vol. 134, No. 1, 01.2011, p. 278-292.

Research output: Contribution to journalArticle

Hao, W, Liu, Y, Liu, S, Walter, S, Grimm, MO, Kiliaan, AJ, Penke, B, Hartmann, T, Rübe, CE, Menger, MD & Fassbender, K 2011, 'Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology', Brain, vol. 134, no. 1, pp. 278-292. https://doi.org/10.1093/brain/awq325
Hao, Wenlin ; Liu, Yang ; Liu, Shirong ; Walter, Silke ; Grimm, Marcus O. ; Kiliaan, Amanda J. ; Penke, B. ; Hartmann, Tobias ; Rübe, Claudia E. ; Menger, Michael D. ; Fassbender, Klaus. / Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. In: Brain. 2011 ; Vol. 134, No. 1. pp. 278-292.
@article{0ccdb008cad44c0d8b166e243a6f00d0,
title = "Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology",
abstract = "Alzheimer's disease is characterized by extracellular deposits of amyloid β peptide in the brain. Increasing evidence suggests that amyloid β peptide injures neurons both directly and indirectly by triggering neurotoxic innate immune responses. Myeloid differentiation factor 88 is the key signalling molecule downstream to most innate immune receptors crucial in inflammatory activation. For this reason, we investigated the effects of myeloid differentiation factor 88-deficient bone marrow cells on Alzheimer's disease-related symptoms and pathology by establishing bone marrow chimeric amyloid β peptide precursor transgenic mice, in which bone marrow cells differentiate into microglia and are recruited to amyloid β peptide deposits. We observed that myeloid differentiation factor 88-deficient bone marrow reconstruction reduced both inflammatory activation and amyloid β peptide burden in the brain. In addition, synaptophysin, a marker of neuronal integrity, was preserved and the expression of neuronal plasticity-related genes, ARC and NMDA-R1, was increased. Thus, myeloid differentiation factor 88-deficient microglia significantly improved the cognitive function of amyloid β peptide precursor protein transgenic mice. Myeloid differentiation factor 88-deficiency enhanced amyloid β peptide phagocytosis by microglia/macrophages and blunted toxic inflammatory activation. Both the expression of amyloid β peptide precursor protein and amyloid β peptide degrading enzymes and also the efflux of amyloid β peptide from brain parenchyma were unaffected by myeloid differentiation factor 88-deficient microglia. By contrast, the activity of β-secretase was increased. β-Secretase is expressed primarily in neurons, with relatively little expression in astrocytes and microglia. Therefore, microglial replenishment with myeloid differentiation factor 88-deficient bone marrow cells might improve cognitive functions in Alzheimer's disease mouse models by enhancing amyloid β peptide phagocytosis and reducing inflammatory activation. These results could offer a new therapeutic option that might delay the progression of Alzheimer's disease.",
keywords = "Alzheimer's disease, inflammation, microglia, MyD88, phagocytosis",
author = "Wenlin Hao and Yang Liu and Shirong Liu and Silke Walter and Grimm, {Marcus O.} and Kiliaan, {Amanda J.} and B. Penke and Tobias Hartmann and R{\"u}be, {Claudia E.} and Menger, {Michael D.} and Klaus Fassbender",
year = "2011",
month = "1",
doi = "10.1093/brain/awq325",
language = "English",
volume = "134",
pages = "278--292",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology

AU - Hao, Wenlin

AU - Liu, Yang

AU - Liu, Shirong

AU - Walter, Silke

AU - Grimm, Marcus O.

AU - Kiliaan, Amanda J.

AU - Penke, B.

AU - Hartmann, Tobias

AU - Rübe, Claudia E.

AU - Menger, Michael D.

AU - Fassbender, Klaus

PY - 2011/1

Y1 - 2011/1

N2 - Alzheimer's disease is characterized by extracellular deposits of amyloid β peptide in the brain. Increasing evidence suggests that amyloid β peptide injures neurons both directly and indirectly by triggering neurotoxic innate immune responses. Myeloid differentiation factor 88 is the key signalling molecule downstream to most innate immune receptors crucial in inflammatory activation. For this reason, we investigated the effects of myeloid differentiation factor 88-deficient bone marrow cells on Alzheimer's disease-related symptoms and pathology by establishing bone marrow chimeric amyloid β peptide precursor transgenic mice, in which bone marrow cells differentiate into microglia and are recruited to amyloid β peptide deposits. We observed that myeloid differentiation factor 88-deficient bone marrow reconstruction reduced both inflammatory activation and amyloid β peptide burden in the brain. In addition, synaptophysin, a marker of neuronal integrity, was preserved and the expression of neuronal plasticity-related genes, ARC and NMDA-R1, was increased. Thus, myeloid differentiation factor 88-deficient microglia significantly improved the cognitive function of amyloid β peptide precursor protein transgenic mice. Myeloid differentiation factor 88-deficiency enhanced amyloid β peptide phagocytosis by microglia/macrophages and blunted toxic inflammatory activation. Both the expression of amyloid β peptide precursor protein and amyloid β peptide degrading enzymes and also the efflux of amyloid β peptide from brain parenchyma were unaffected by myeloid differentiation factor 88-deficient microglia. By contrast, the activity of β-secretase was increased. β-Secretase is expressed primarily in neurons, with relatively little expression in astrocytes and microglia. Therefore, microglial replenishment with myeloid differentiation factor 88-deficient bone marrow cells might improve cognitive functions in Alzheimer's disease mouse models by enhancing amyloid β peptide phagocytosis and reducing inflammatory activation. These results could offer a new therapeutic option that might delay the progression of Alzheimer's disease.

AB - Alzheimer's disease is characterized by extracellular deposits of amyloid β peptide in the brain. Increasing evidence suggests that amyloid β peptide injures neurons both directly and indirectly by triggering neurotoxic innate immune responses. Myeloid differentiation factor 88 is the key signalling molecule downstream to most innate immune receptors crucial in inflammatory activation. For this reason, we investigated the effects of myeloid differentiation factor 88-deficient bone marrow cells on Alzheimer's disease-related symptoms and pathology by establishing bone marrow chimeric amyloid β peptide precursor transgenic mice, in which bone marrow cells differentiate into microglia and are recruited to amyloid β peptide deposits. We observed that myeloid differentiation factor 88-deficient bone marrow reconstruction reduced both inflammatory activation and amyloid β peptide burden in the brain. In addition, synaptophysin, a marker of neuronal integrity, was preserved and the expression of neuronal plasticity-related genes, ARC and NMDA-R1, was increased. Thus, myeloid differentiation factor 88-deficient microglia significantly improved the cognitive function of amyloid β peptide precursor protein transgenic mice. Myeloid differentiation factor 88-deficiency enhanced amyloid β peptide phagocytosis by microglia/macrophages and blunted toxic inflammatory activation. Both the expression of amyloid β peptide precursor protein and amyloid β peptide degrading enzymes and also the efflux of amyloid β peptide from brain parenchyma were unaffected by myeloid differentiation factor 88-deficient microglia. By contrast, the activity of β-secretase was increased. β-Secretase is expressed primarily in neurons, with relatively little expression in astrocytes and microglia. Therefore, microglial replenishment with myeloid differentiation factor 88-deficient bone marrow cells might improve cognitive functions in Alzheimer's disease mouse models by enhancing amyloid β peptide phagocytosis and reducing inflammatory activation. These results could offer a new therapeutic option that might delay the progression of Alzheimer's disease.

KW - Alzheimer's disease

KW - inflammation

KW - microglia

KW - MyD88

KW - phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=78650687363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650687363&partnerID=8YFLogxK

U2 - 10.1093/brain/awq325

DO - 10.1093/brain/awq325

M3 - Article

C2 - 21115468

AN - SCOPUS:78650687363

VL - 134

SP - 278

EP - 292

JO - Brain

JF - Brain

SN - 0006-8950

IS - 1

ER -